Celldex Therapeutics, Inc.
CLDXNASDAQHealthcareBiotechnology
As of Oct 23, 2026 close
- Market cap
- $2.28B
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $22.10$45.14
- Volume (live)
- -
- Avg. volume (3M)
- 1.98M
Celldex Therapeutics (CLDX) Stock Price & Financial Analysis
Celldex Therapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $28.20 - $29.38 |
|---|---|
| 52-Week High | $45.14 |
| 52-Week Low | $22.10 |
| Open | $28.95 |
| Volume (last close) | 879.73K |
| Average Volume (3M) | 1.98M |
| Revenue (TTM) | 112.00K |
|---|---|
| Net Income (TTM) | -300.59M |
| Free Cash Flow (TTM) | -241.82M |
| EPS (TTM) | −$4.34 |
| Profit Margin | -268385.71% |
| Operating Margin | -290948.21% |
| Return on Equity (ROE) | -42.07% |
| Debt to Equity | 0.01 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Market Cap | 2.28B |
|---|---|
| Shares Outstanding | 77.84M |
| Price to Sales (P/S) | 20328.75 |
| Price to Book (P/B) | 3.19 |
| EV/EBITDA | -7.12 |
| 50-Day MA | $36.10 |
|---|---|
| 200-Day MA | $32.53 |
| 1-Year Change | +10.32% |
Source: Market prices and company fundamentals. Data as of Oct 23, 2026. Data sources and methodology
Celldex Therapeutics at a Glance
As of the Oct 23, 2026 close, Celldex Therapeutics (CLDX) has a market capitalization of $2.28B. The stock trades at 20328.8× sales. Over the trailing twelve months it lost $300.59M on revenue of $112.00K and burned $241.82M of free cash flow. Revenue fell 97.3% year over year.
As of its latest reported balance sheet, it holds $47.45M in cash and securities against $4.90M of debt, a net cash position of $42.55M.
Celldex Therapeutics does not currently pay a dividend.
The share price is up 10.3% over the past year. At $29.25 (the Oct 23, 2026 close) it sits within its 52-week range of $22.10 to $45.14, below its 200-day moving average of $32.53.
Based on 13 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $66.17, 126.2% above the Oct 23, 2026 close.
Frequently Asked Questions About Celldex Therapeutics
What is the current stock price for CLDX?
As of the Oct 23, 2026 close, CLDX stock trades at $29.25. The 52-week range is $22.10–$45.14, with a day range of $28.20–$29.38.
What is the P/E ratio for CLDX?
The P/E ratio (Price-to-Earnings) for CLDX is shown in the Key Statistics section. This valuation metric helps compare Celldex Therapeutics, Inc. to industry peers.
Does CLDX pay dividends?
Celldex Therapeutics does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for CLDX?
Based on ratings from 13 professional analysts over the last 90 days, the consensus for CLDX is Buy. The average 12-month price target is $66.17, a 126.2% upside from the Oct 23, 2026 close of $29.25.
What is the market cap of CLDX?
As of the Oct 23, 2026 close, Celldex Therapeutics's market capitalization is $2.28B, classifying it as a mid-cap company. Celldex Therapeutics operates in the Healthcare sector within the Biotechnology industry.